Investigating the role of potential genetic markers that can predict risk for steroid refractory inflammatory bowel disease
Background - Inter-individual variation in response to treatment by corticosteroids (CS) is an important problem in the management of inflammatory bowel disease (IBD) patient’s. This problem is even more prominent in children, the prevalence of steroid dependence (~40%) in whom is extremely high. Steroid refractoriness has a considerable impact on the physical and psychological development of these children, also imposing high medical costs related to treatment. Active disease, as opposed to quiescent, increases medical costs 2-3 times in ambulatory patients and 20 times in hospitalized cases. Identifying markers that could predict steroid response is therefore a high clinical priority. Previous attempts to investigate potential clinical and demographic markers have been equivocal, highlighting the need for further investigations of other predictive markers. It is well known that the action of CS entails complex processes controlled by genetic factors. Two genes, the ABCB1 gene, which belongs to the family of trans-membrane transporters, and the NR3C1 gene, coding for the glucocorticoid receptor, are major elements of the pathway. We postulated that inter-individual variations in these genes may play a role in the observed variability of the response to CS and could serve as potential predictors.  Objectives - We aimed to: (1) examine the burden of steroid refractoriness in children diagnosed with CD and explore the potential clinical/demographic factors related to CS response; (2) study the association between DNA variants in the ABCB1 gene and CS response; (3) investigate the associations between DNA variants in the NR3C1 gene and CS response.  Methods - We investigated these objectives in a cohort of CD patients recruited from two tertiary paediatric gastroenterology clinics from Ottawa (CHEO) and Montreal (HSJ). CD patients diagnosed prior to age 18 using standard clinical, radiological, endoscopic and histopathological criteria were included. Published criteria were adapted to define CS-resistance and dependence. DNA acquired from blood and/or saliva was genotyped for variations across the ABCB1 and NR3C1 genes selected using the tag-SNP methodology. The frequencies of steroid resistance and dependence were estimated assuming a binomial distribution. Associations between clinical/demographic variables and steroid responses were examined using logistic regression modeling after accounting for potential confounding variables. Associations between ABCB1 and NR3C1 genes’ variants and steroid responses were examined using logistic regression assuming different models of inheritance. Multi-marker associations were examined via haplotype analysis. Un-genotyped variants in the genes were imputed using HAPMAP data as the reference panel and associations with imputed SNPs examined using standard methods.  Results - Among 645 CD patients diagnosed at the study centers, 364 (56.2%) received corticosteroids during the first year since diagnosis. The majority of patients were male (54.9%), had inflammatory (84.6%), ileo-colonic (51.7%) disease phenotypes at diagnosis and were Caucasians (95.6%). Eight percent of patients developed CS-resistance and 40.9% became CS-dependent. Younger age at diagnosis (OR=1.34, 95% CI: 1.03-3.01, p=0.040), coexisting upper digestive tract involvement (OR=1.35, 95% CI: 1.06-3.07, p=0.031) and concomitant immunomodulators use (OR=0.35, 95% CI: 0.16-0.75, p=0.007) were significantly associated with CS-dependency in multivariate analysis. From among the 27 markers genotyped across the ABCB1 (n=14) and NR3C1 genes (n=13), all except one in NR3C1 gene (rs258751, excluded) were in Hardy-Weinberg Equilibrium. For ABCB1, the rare allele of rs2032583 (OR=0.56, 95% CI: 0.34-0.95, p=0.029) and heterozygous genotype (OR=0.52, 95% CI: 0.28-0.95, p=0.035) conferred protection from CS dependency. A 3-marker haplotype including the functional SNP rs1045642 was associated with CS-dependence (empiric p-value=0.004). On imputation 24 intronic SNPs and six haplotypes were statistically significantly associated with CS dependence. None of these associations however maintained significance after corrections for multiple comparisons.  For the NR3C1 gene 3 SNPs, rs10482682 (OR=1.43, 95% CI: 0.99-2.08, p=0.047), rs6196 (OR=0.55, 95% CI: 0.31-0.95, p=0.024), and rs2963155 (OR=0.64, 95% CI: 0.42-0.98, p=0.039), showed associations under an additive model whereas rs4912911 (OR=0.37, 95% CI: 0.13-1.00, p=0.03) and rs2963156 (OR=0.32, 95% CI: 0.07-1.12, p=0.047) showed associations under a recessive model. Two haplotypes encompassing these 5 SNPs (AAACA and GGGCG) were significantly (empirical p=0.006 and 0.01 respectively) were associated with CS-dependence. On imputation 19 SNPs were associated with CS-dependence. Two multi-marker haplotypes (p-values=0.001 each) including genotyped and imputed SNPs conferred susceptibility for CS-dependency. Conclusions - Our studies suggest that the burden of steroid dependence is high among children with CD. Children diagnosed at a younger age, those with co-existent upper tract disease and with variations in the ABCB1 and NR3C1 genes were more likely to become CS dependent.
Genetic epidemiology Genetic association study Gene candidate Inflammatory bowel disease Crohn’s disease Drug response Inter-individual variations ABCB1 ABCB1 NR3C1 NR3C1 Single nucleotide polymorphisms (SNPs)